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Aims: To determine whether specific lipid parameters are better predictors of cardiovascu-
lar disease (CVD) in Japanese mild-to-moderate hypercholesterolemic patients with and
without diabetes.
Methods: Mildly or moderately hypercholesterolemic patients with no history of CVD
received diet therapy or diet therapy plus pravastatin. In this post-hoc subanalysis, 5-year
data from 3170 patients (668 diabetes, 2502 non-diabetes) on diet therapy alone were used to
compare lipid parameters as predictors of CVD. We examined the data by tertiles, using
hazard ratio (HR) per one-standard deviation (SD) increment (decrease for high-density
lipoprotein cholesterol, HDL-C), x2 value, receiver operating characteristic curve analysis,
and spline analysis.
Results: In mild-to-moderate hypercholesterolemic patients with diabetes, increased
total cholesterol (TC)/HDL-C, low-density lipoprotein cholesterol (LDL-C)/HDL-C and
decreased HDL-C were strongly associated with increased incidence of CVD (tertile
analysis). In non-diabetes, increased non-HDL-C, and LDL-C/HDL-C were significantly
associated with increased incidence of CVD. A one-SD decrease in HDL-C and a one-SD
increment in non-HDL-C, TC/HDL-C, and LDL-C/HDL-C were significantly associated
with increased HRs for CVD in both diabetes and non-diabetes. Linear CVD risk increases
were found for non-HDL-C in diabetes and for non-HDL-C and HDL-C in non-diabetes
(spline analysis).
Conclusions: In mild-to-moderate hypercholesterolemia, CVD risk prediction by stratifica-
tions of single or combination of traditional lipid parameter values illustrates various
patterns. Parameters including HDL-C are better predictors of cardiovascular risk than only
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using TC or LDL-C alone. Non-HDL-C could be the most useful lipid parameter to assess CVD
risk, considering it is easy to calculate and less affected by food intake.
# 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cardiovascular disease (CVD), including coronary heart
disease (CHD) and stroke, is a major cause of death worldwide.
Cardiovascular risk depends on the presence of comorbidities
such as dyslipidemia, hypertension, overweight, and smoking
[1]. Hypercholesterolemia is a particularly important risk
factor and is managed by lipid-modifying therapies.
The assessment and management of cardiovascular risk is
required for patients with diabetes mellitus, who often have
hypercholesterolemia [2–4]. Patients with type 2 diabetes have
an abnormal atherogenic lipid profile (low high-density
lipoprotein cholesterol, HDL-C; high small dense low-density
lipoprotein cholesterol, LDL-C; and high triglycerides, TGs)
and double the cardiovascular risk of patients without
diabetes [5].
Serum concentrations of lipids are used to assess cardio-
vascular risk and guide lipid-modifying therapies in patients
with and without diabetes. A serum lipid profile commonly
measured comprises total cholesterol (TC), HDL-C, LDL-C, and
TGs. The ratios of TC/HDL-C and LDL-C/HDL-C also are useful.
Recent guidelines have added non-HDL-C to the list of
recommended variables for assessing cardiovascular risk
[6,7]. Non-HDL-C (calculated as TC minus HDL-C) is widely
used.
However, there is a lack of consensus on how to assess
cardiovascular risk in patients with type 2 diabetes [8]. Few
studies have compared the relative value of different lipid
variables in predicting cardiovascular events in patients with
diabetes especially in comparison with subjects without
diabetes. It could be potentially important with respect to
whether cardiovascular risk assessment and lipid-lowering
therapy should be modified according to diabetes status.
Furthermore, most of the key studies were done in Western
countries, which have a higher incidence of CHD than in
Japan. In Western countries, CHD causes the greater majority
of deaths of patients with diabetes [9]. In contrast, cancer is the
leading cause of death in Japanese patients with diabetes [10].
We conducted a subanalysis of the Management of
Elevated Cholesterol in the Primary Prevention Group of Adult
Japanese (MEGA) study [11] to evaluate which lipid parameters
best predict cardiovascular events in mild-to-moderate
hypercholesterolemia patients with and without diabetes in
the diet alone group.
2. Methods
2.1. Patients
The details of the MEGA study have been described elsewhere
[11]. Briefly, 7832 patients (2476 men and 5356 postmeno-
pausal women) aged 40–70 years with mild-to-moderatehypercholesterolemia (TC, 5.7–7.0 mmol/L [220–270 mg/dL])
and no history of CHD or stroke were randomly allocated to
diet therapy alone or diet therapy plus pravastatin (10–20 mg/
day, the approved dose in Japan) for a mean follow-up period
of 5.3 years. Patients in both groups were counseled to follow
the National Cholesterol Education Program step I diet [12]
throughout the study period. Concomitant treatment for
complications was unrestricted in both groups.
The primary composite endpoint was the first occurrence
of CHD events, that is, fatal or nonfatal myocardial infarction,
angina pectoris, cardiac or sudden death, and coronary
revascularization. Secondary endpoints included all strokes,
CHD plus stroke, all CVD events, and total mortality. Patients
were evaluated by their attending physicians at 1, 3, and 6
months after the start of follow-up and every 6 months
thereafter. Health checks at each clinic visit included
biochemical tests and assessment of patient adherence to
treatment. For each event, detailed information was evaluated
by the Endpoints Committee under blinding according to
established criteria [11,12].
Throughout the study period, non-fasting TC, HDL-C, TGs,
and lipoprotein (a) were measured centrally at the same
laboratory using methods standardized by the Centers for
Disease Control and Prevention (Atlanta, GA, USA). LDL-C was
estimated using the Friedewald formula [13].
All procedures followed were in accordance with the
ethical standards of the responsible committee on human
experimentation (institutional and national) and with the
Helsinki Declaration of 1975, as revised in 2008. Informed
consent was obtained from all patients for being included in
the study.
2.2. Tertile analysis
The present study was a post-hoc subanalysis using 5-year
follow-up data to reduce potential bias from the high drop-in
rate for statin use in patients allocated to diet therapy alone,
which was caused by an additional follow-up period. The 3170
patients with type 2 diabetes (n = 668) and without diabetes
(n = 2502) who received diet therapy alone were divided into
tertiles according to their baseline data for each lipid
parameter to compare the incidence of CHD, CHD plus stroke,
and all CVD events in patients with and without diabetes.
Diabetes was defined as a baseline fasting glucose 7.0 mmol/
L, HbA1c  6.5% (48 mmol/mol; National Glycohemoglobin
Standardization Program, NGSP) [14], or taking an oral
hypoglycemic agent.
2.3. Hazard ratios
Hazard ratios (HRs) and 95% confidence intervals (CIs) were
estimated using the multivariate Cox proportional hazards
model adjusted by sex, age, body mass index (BMI), smoking
status (current/past/never), alcohol intake, aspirin use, oral
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tertile of each variable as the reference group.
2.4. Pearson’s chi-squared test (x2)
We used the x2 likelihood ratio test to evaluate the strength of
associations between lipid variables and the incidence of CHD,
CHD plus stroke, and all CVD events.
The corresponding P values were estimated from the
regression coefficient based on the Cox proportional hazards
model adjusted by sex, age, smoking, and hypertension.
2.5. Receiver operating characteristic curve analysis
The discriminatory power of the lipid variables for CVD was
compared using the receiver operating characteristic (ROC)
curve analysis, applying various thresholds to the predicted
probability obtained from the multiple logistic regression
model. The area-under-the-curve (AUC) was calculated by
integrating the area between the ROC curve and the diagonal
line where sensitivity is equal to one specificity based on the
trapezoidal rule.
2.6. Spline analyses
Multivariable Cox proportional hazards models with a
restricted quadratic spline based on three knots for the
quartiles were also used to explore potential nonlinear
relations [15]. The multivariable models were simultaneously
adjusted by sex and age, smoking status, and hypertension. All
P values were two-sided, and the significance level was 0.05.
All statistical analyses were done using SAS package version
9.2 (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Patient baseline characteristics
Table 1 shows the baseline characteristics of the patients with
and without diabetes. The patients in the two groups were
similar in age. However, the diabetes group contained a
significantly higher percentage of men, as well as patients
with a history of smoking or drinking alcohol. Patients with
diabetes also had significantly higher values for body mass
index, systolic blood pressure, and some lipid variables (LDL-
C/HDL-C, non-HDL-C, and TGs). HDL-C was significantly lower
in patients with diabetes.
3.2. Tertile analysis of lipid variables and cardiovascular
events
There were 70 CVD events (34 CHD events, 24 strokes, and 12
other CVD events) in 668 patients with diabetes. Table 2
shows hazard ratios of all cardiovascular events according
to lipid variables (for individual CVD events, see Supple-
mental Table 1). Patients with higher values for lipid
variables other than HDL-C had higher cardiovascular risk.
Conversely, higher HDL-C was associated with lower
cardiovascular risk.Diabetes was associated with higher cardiovascular risk.
Patients with diabetes had 13.00 events/1000 person-years for
CHD, 17.60 events/1000 person-years for CHD plus cerebral
infarction, and 20.14 events/1000 person-years for all CVD.
These values are over three times higher than the respective
values for patients without diabetes (3.00 events/1000 person-
years for CHD, 4.34 events/1000 person-years for CHD plus
cerebral infarction, and 6.23 events/1000 person-years for
CVD).
The tertile analysis, demonstrated that decreased HDL-C
and increased TC/HDL-C and LDL-C/HDL-C were the signifi-
cant predictor for CVD events in patients with diabetes
(Table 2). A similar relationship was found in CHD and CHD
plus cerebral infarction (Supplement Table 1). In contrast, in
patients without diabetes, increased non-HDL-C and LDL-C/
HDL-C were identified as significant risk predictors for CVD
events. All these lipid variables were more predictive than
LDL-C for any type of events and regardless of presence and
absence of diabetes.
3.3. Hazard ratios for cardiovascular events
Table 3 shows the HRs of all cardiovascular events per one-
standard deviation (SD) increment for the lipid variable and
decrease for HDL-C (for individual CVD events, see Supple-
mental Table 2). In this analysis, HDL-C and non-HDL-C were
significantly associated with increased HRs for each event in
patients with and without diabetes compared with other lipid
variables including LDL-C.
3.4. x2 values
In patients with diabetes, there were no apparent differences
in the x2 values for the HDL-C, non-HDL-C, TC/HDL-C, and
LDL-C/HDL-C and were higher than those for the other lipid
variables (Table 2 and Supplemental Table 2). The x2 values
were highest for HDL-C.
3.5. Receiver operating characteristic curve analysis
For patients with diabetes, AUC values were similar for CVD
events (Table 3, range, 0.71–0.74). For HDL-C, non-HDL-C, TC/
HDL-C, and LDL-C/HDL-C a one-SD increment was associated
with a significant change in the incidence of CVD events.
Meanwhile, in patients without diabetes, a one-SD increment
in addition to above parameters, TGs/HDL-C for CVD events
significantly increased the incidence of these events and had
higher x2 values. AUC values were similar for CVD events
(range, 0.77–0.78; Table 3). Similar results were found for CHD,
and CHD plus cerebral infarction (Supplemental Table 2).
3.6. Spline analyses
Spline analyses were conducted to assess the sensitivity of
lipid parameters for assessing cardiovascular risk. Spline
analyses were performed for the lipid variables that showed
visible associations with the incidence of all three groups of
cardiovascular events. The non-HDL-C in patients with
diabetes (Fig. 1a) and non-HDL-C and HDL-C in patients
without diabetes (Fig. 1b) were seen to be almost linear.
Table 1 – Patient baseline characteristics.
Patients without diabetes
(n = 2502)
Patients with diabetes
(n = 668)
Total (N = 3170) P
Age (years)§ 58.32  7.14 58.66  6.97 58.39  7.10 0.24
Sex [n (%)]
Male 720 (28.8) 295 (44.2) 1015 (32.0) <0.01
Female 1782 (71.2) 373 (55.8) 2155 (68.0)
BMI (kg/m2)§ 23.68  2.96 24.27  3.32 23.80  3.05 0.01
BMI  25 (%) 756 (30.2) 250 (37.4) 1006 (31.2) <0.01
Hypertension [n (%)] 1032 (41.2) 285 (42.7) 1317 (41.5) 0.51
Systolic blood pressure (mmHg)§ 131.73  16.41 135.03  17.48 132.43  16.69 0.01
Diastolic blood pressure (mmHg)§ 78.65  9.91 79.13  10.49 78.76  10.04 0.28
TC (mmol/L)§ 6.28  0.31 6.27  0.32 6.27  0.31 0.57
LDL-C (mmol/L)§ 4.05  0.43 4.05  0.49 4.05  0.45 0.62
HDL-C (mmol/L)§ 1.50  0.38 1.41  0.40 1.48  0.39 0.01
Non-HDL-C (mmol/L)§ 4.77  0.48 4.86  0.49 4.79  0.48 0.01
LDL-C/HDL-C 2.89  0.87 3.08  0.91 2.92  0.89 <0.01
TGs (mmol/L) [median (min-max)] 1.4 (0.5–10.6) 1.6 (0.5–14.9) 1.4 (0.5–14.9) <0.01
TGs (log transformed) 0.37 0.52 0.4 0.01
Fasting blood glucose (mmol/dL)§ 5.30  0.60 8.40  2.20 6.00  1.70 0.01
HbA1c (%)
§,y 5.7  0.79 7.5  1.64 6.3  1.48 0.01
Diabetes therapy [n (%)]
Diet therapy 214 (32.0)
Insulin 72 (10.8)
Sulfonylureas 290 (43.4)
a-Glucosidase inhibitors 145 (21.7)
Others 24 (3.6)
Hypertension therapy [n (%)]
No medication 954 (38.1) 259 (28.8) 1213 (38.3) 0.76
ACE inhibitor 281 (11.2) 102 (15.3) 383 (12.1) 0.004
ARB 22 (0.9) 6 (0.9) 28 (0.9) 0.96
a-Blocker 55 (2.2) 26 (3.9) 81 (2.6) 0.01
b-Blocker 208 (8.3) 41 (6.1) 249 (7.9) 0.06
ab-Blocker 47 (1.9) 10 (1.5) 57 (1.8) 0.51
Calcium channel blocker 632 (25.3) 187 (28.0) 819 (25.8) 0.15
Diuretic 78 (3.1) 23 (3.4) 101 (3.2) 0.67
Others 27 (1.1) 7 (1.0) 34 (1.1) 0.94
Smoking status [n (%)]
Non-smoker 2054 (82.1) 474 (71.0) 2528 (79.7) 0.01
Former or current 448 (17.9) 193 (28.9) 641 (20.2)
Alcohol consumption [n (%)]
No 1783 (71.3) 442 (66.2) 2225 (70.2) 0.01
Yes 719 (28.7) 225 (33.7) 944 (29.8)
Hypertension 1032 (42.7) 258 (41.2) 1317 (41.5) 0.51
BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TGs,
triglycerides; HbA1c, glycated hemoglobin; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.
§ Mean  SD.
y HbA1c values were converted from Japan Diabetes Society (JDS) values to National Glycohemoglobin Standardization Program (NGSP) values
using the following formula: HbA1c (NGSP equivalent value) (%) = 1.02  HbA1c (JDS value) (%) + 0.25%.
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Diabetes has been identified as a strong independent risk
factor for CHD [16]. Nevertheless, it is well known that Japan
is a country that has low incidence of CHD, although the
prevalence of diabetes in Japan is proportionally higher
than in Western countries [17]. On the other hand, Japanese
have proportionally higher HDL-C levels than Western
populations [18–21], which may be associated with lower
incidence of CHD. Therefore, to elaborate the relationship
between lipids, especially with combination of HDL-C, andCVD in diabetes will provide additional information to
establish the optimal lipid management strategy in diabetic
patients.
The present subanalysis revealed differences in the ability
of lipid parameters to predict cardiovascular events in patients
with and without diabetes. Although a total 7832 patients were
included in the main analysis of the MEGA study, the present
analysis was conducted using only the data from the diet
alone group, and excluding patients who started statins during
follow-up to eliminate any possible confounding effects
because of pleiotropic effects of the statin on CVD which
were suggested previously [22].
Table 2 – Hazard ratios of all cardiovascular events according to lipid variable stratified by tertile.
Patients without diabetes Patients with diabetes
Range No. of
events (/1000
person-years)
Hazard
ratio
(95% CI)
P
(P for all)
Range No. of
events (/1000
person-years)
Hazard
ratio
(95% CI)
P (P for all)
TC (mmol/L) 5.7–6.1 18/833 (4.83) (0.18) 5.7–6.1 22/224 (22.3) (0.79)
6.1–6.4 23/827 (6.18) 1.35 (0.73–2.50) 0.34 6.1–6.4 17/225 (18.0) 0.83 (0.44–1.56) 0.56
6.4–7.0 29/842 (7.65) 1.75 (0.97–3.15) 0.06 6.4–7.0 19/219 (20.1) 1.02 (0.54–1.90) 0.96
LDL-C (mmol/L) 1.1–3.9 18/834 (4.80) (0.16) 0.2–3.8 15/222 (15.2) (0.14)
3.9–4.2 22/829 (5.94) 1.30 (0.69–2.43) 0.41 3.8–4.3 21/222 (22.2) 1.79 (0.91–3.51) 0.09
4.2–5.2 30/839 (7.94) 1.76 (0.97–3.20) 0.06 4.3–5.3 22/224 (23.3) 1.89 (0.96–3.73) 0.07
HDL-C (mmol/L) 1.6–3.7 11/836 (2.91) (0.05) 1.5–4.2 10/221 (10.2) (0.03)
1.3–1.6 23/843 (6.06) 1.75 (0.84–3.62) 0.13 1.2–1.5 24/226 (25.1) 2.53 (1.18–5.43) 0.02
0.6–1.3 36/823 (9.85) 2.37 (1.17–4.82) 0.02 0.7–1.2 24/221 (25.5) 2.68 (1.25–5.77) 0.01
TGs
(log transformed)
0.8–0.1 15/834 (3.97) (0.50) 0.7–0.3 17/222 (17.5) (0.70)
0.1–0.5 22/833 (5.90) 1.13 (0.58–2.20) 0.71 0.3–0.7 21/224 (21.7) 1.33 (0.69–2.55) 0.40
0.5–2.4 33/835 (8.88) 1.43 (0.75–2.73) 0.27 0.7–2.7 20/222 (21.3) 1.20 (0.60–2.39) 0.61
Non-HDL-C
(mmol/L)
2.6–4.6 11/838 (2.91) (0.02) 2.2–4.7 16/222 (16.3) (0.07)
4.6–5.0 23/829 (6.21) 1.88 (0.91–3.90) 0.09 4.7–5.1 16/224 (16.7) 1.09 (0.54–2.23) 0.81
5.0–6.1 36/835 (9.62) 2.75 (1.37–5.53) 0.00 5.1–5.9 26/222 (27.8) 1.94 (1.02–3.71) 0.04
TC/HDL-C 1.70–3.86 11/834 (2.91) (0.06) 1.52–4.26 11/222 (11.3) (0.04)
3.87–4.81 24/834 (6.39) 1.79 (0.87–3.70) 0.11 4.26–5.09 22/223 (22.9) 2.28 (1.08–4.82) 0.03
4.81–10.93 35/834 (9.46) 2.35 (1.15–4.80) 0.02 5.10–9.23 25/223 (26.5) 2.52 (1.20–5.30) 0.01
LDL-C/HDL-C 0.62–2.45 11/834 (2.93) (0.02) 0.29–2.70 9/222 (8.98) (0.00)
2.45–3.19 23/834 (6.11) 1.87 (0.90–3.88) 0.09 2.70–3.36 26/223 (27.6) 3.64 (1.68–7.86) 0.00
3.19–8.16 36/834 (9.70) 2.65 (1.32–5.33) 0.01 3.36–6.25 23/223 (24.6) 2.98 (1.36–6.56) 0.01
TGs/HDL-C 0.16–0.74 12/834 (3.18) (0.18) 0.19–0.90 17/222 (17.3) (0.72)
0.74–1.29 23/834 (6.11) 1.46 (0.72–2.97) 0.30 0.90–1.60 20/223 (20.9) 1.29 (0.67–2.50) 0.45
1.30–9.43 35/834 (9.47) 1.91 (0.95–3.83) 0.07 1.61–19.57 21/223 (22.3) 1.26 (0.63–2.52) 0.51
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TGs, triglycerides.
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were some differences in risk profile between diabetes and
non-diabetes, although HDL-C, non-HDL-C, TC/HDL-C, and
LDL-C/HDL-C were similarly associated with the incidence ofTable 3 – Hazard ratio per one-SD increment (decrease for HD
Hazard ratio (95% CI) 
Patients without diabetes
TC 1.02 (1.00–1.04) 
LDL-C 1.01 (1.00–1.02) 
HDL-C 0.97 (0.96–1.00) 
TGs (log transformed) 1.65 (0.97–2.81) 
Non-HDL-C 1.02 (1.01–1.04) 
TC/HDL-C 1.35 (1.09–1.66) 
LDL-C/HDL-C 1.36 (1.04–1.77) 
TGs/HDL-C 1.13 (1.04–1.23) 
Patients with diabetes
TC 1.01 (0.99–1.03) 
LDL-C 1.01 (1.00–1.02) 
HDL-C 0.97 (0.95–0.99) 
TGs (log transformed) 1.19 (0.72–1.96) 
Non-HDL-C 1.02 (1.01–1.04) 
TC/HDL-C 1.30 (1.07–1.58) 
LDL-C/HDL-C 1.39 (1.07–1.82) 
TGs/HDL-C 1.05 (0.99–1.11) 
SD, standard deviation; AUC, area-under-the-curve; HDL-C, high-density
TC, total cholesterol; TGs, triglycerides.each category of cardiovascular events. In non-diabetes
patients, TGs/HDL-C were additionally identified as significant
predictors. In addition, our ROC analysis suggested that
predictability for CVD is not so different among thoseL-C): all cardiovascular events and area under the curve.
x2 P AUC (95% CI)
3.51 0.06 0.77 (0.72–0.82)
1.78 0.18 0.77 (0.71–0.82)
5.90 0.02 0.77 (0.72–0.82)
3.41 0.06 0.77 (0.71–0.82)
9.94 <0.01 0.78 (0.72–0.83)
7.77 0.01 0.77 (0.72–0.82)
5.09 0.02 0.77 (0.72–0.82)
9.26 <0.01 0.77 (0.72–0.82)
0.38 0.54 0.71 (0.65–0.78)
2.94 0.09 0.72 (0.66–0.79)
7.84 0.01 0.74 (0.68–0.81)
0.46 0.50 0.72 (0.65–0.78)
7.20 0.01 0.73 (0.67–0.80)
6.83 0.01 0.74 (0.68–0.80)
5.86 0.02 0.73 (0.67–0.80)
2.71 0.10 0.72 (0.66–0.79)
 lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
Fig. 1 – Spline curves for cardiovascular disease by lipid variable in (a) patients with diabetes and (b) patients without
diabetes. Solid lines, relative risk; broken lines, 95% CIs. HDLC, high-density lipoprotein cholesterol; LDLC, low-density
lipoprotein cholesterol; TC, total cholesterol.
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Study [23], HRs stratified by the SD of TC, LDL-C, non-HDL-C,
and TC/HDL-C were determined by the Cox proportional
hazards model in patients with no history of diabetes. As in
the present subanalysis, they showed that non-HDL-C and TC/
HDL-C were significant predictors of cardiovascular events.
Furthermore, more recent results showed that LDL-C/HDL-C
and TC/HDL-C were significant predictors of CVD (evaluated
by intima-media thickness) in Japanese patients with type 2
diabetes [24].
In the population in this analysis, no difference in LDL-C
between patients with and without diabetes was found,
probably due to the narrow range of TC for study enrollment
(5.7–7.0 mmol/L). However, a difference in TGs and non-HDL-C
level and incidence of CVD between diabetes and non-diabetes
was observed in the present analysis. In particular, in patients
with diabetes, hyperlipidemia is characterized by very low
density lipoprotein cholesterol (VLDL-C), increased levels of
small dense LDL-C and TGs, and decreased levels of HDL-C.
Non-HDL-C includes LDL-C, intermediate-density lipoprotein
cholesterol, and VLDL-C, chylomicron remnants, and lipopro-
tein (a), which are known risk factors for CVD as well as LDL-C
[25] may enhance the ability to predict CVD. Therefore, to use
non-HDL-C would be more appropriate in cardiovascular risk
prediction for patients with diabetes [26–28]. The clear linear
relationship between non HDL-C and CVD that was found in
our spline analysis also supports the usefulness of non-HDL-C.
Other advantages to using non-HDL-C to assess cardiovascu-
lar risk are the lesser effect of food intake and its ease of
calculation [29,30], and these are also supported by previous
studies [26–28] as well as recent guidelines [6].
Different lipid parameters may predict cardiovascular
risk in patients with high and low HDL-C. A novel finding of
the present analysis was the high sensitivity of HDL-C to
predict cardiovascular events in patients with and without
diabetes. In the MEGA study, low HDL-C (<1.04 mmol/L
[40 mg/dL]) was the only lipid parameter identified as a risk
factor for CHD [31]. The mean baseline HDL-C level in
patients with diabetes in the present analysis was
1.41 mmol/L (54.6 mg/dL), which is higher than the baseline
HDL-C of patients in similar studies done in Western
countries. This difference in baseline HDL-C level of
Japanese and Western patients may mean that any decrease
in HDL-C is associated with a greater increase in cardiovas-
cular risk in Japanese patients.
Hypoglycemia agents have been reported to modify lipid
parameters in patients with diabetes [32]. In the MEGA study,
almost 70% of the patients received one or more hypoglyce-
mia agent. Sulfonylureas were used by 43.4% of patients, and
21.7% of patients received a-glucosidase inhibitors. Previous
reports have suggested that all hypoglycemic agents are
associated with decrease in TC, but different effects were
observed in TGs and HDL-C with different hypoglycemic
agents. a-Glucosidase inhibitors increased HDL-C and de-
creased TGs, while sulfonylurea decreased HDL-C and had no
effect on TGs. A significant relationship was observed
between each lipid parameter and the risk of CVD in patients
with diabetes in relation to the lipid modifications which
included the lipid modification effect caused by the hypogly-
cemic agents. In the present analysis, nearly 40% of thepatients with and without diabetes had hypertension. The
ratio of hypertensive patients was numerically higher and the
average systolic blood pressure was significantly higher in
patients with diabetes than those without diabetes. However,
because the presence of hypertension and the type of
antihypertensive medication would not affect lipid levels, it
seems these do not need to be considered in the present
analysis. Indeed, the blood pressure levels were similar
throughout the entire study in the diet alone group and
diet + pravastatin group [33].
A limitation of the present analysis is the limited number of
patients with diabetes (n = 668) in the MEGA study. Our study
population contained about four times as many patients
without diabetes as those with diabetes. We believe that the
issue of the small number of patients with diabetes had no
influence on the present results, because this finding was
based on the adjusted hazard ratio. Fewer cardiovascular
events occurred in the MEGA study than in previous Western
studies. Studies including more patients with diabetes should
be performed.
Another limitation is that apolipoprotein was not mea-
sured. A recent metaanalysis of clinical studies of statins
showed that the apolipoprotein (apo)-B/apo-A1 ratio is
closely associated with the LDL-C/HDL-C ratio and is a better
predictor of cardiovascular risk than other lipid parameters
routinely used in clinical practice [34]. Furthermore, the
importance of measuring the apo-B/apo-A1 ratio in addition
to traditional lipid ratios to assess cardiovascular risk was
shown by a subanalysis of the Fenofibrate Intervention and
Event Lowering in Diabetes (FIELD) study, which evaluated
the efficacy of fenofibrate to prevent cardiovascular events in
patients with type 2 diabetes. This showed the importance of
measuring apo-B/apo-A1 ratio as well as traditional lipid
ratios to assess cardiovascular risk [35]. However, our present
results may support the findings of the metaanalysis and the
FIELD study subanalysis, because the LDL-C/HDL-C ratio may
reflect the apo-B/apo-A1 ratio (apo-B and apo-A1 are the
primary apolipoprotein components of LDL-C and HDL-C,
respectively).
This analysis included only patients with hypercholester-
olemia; there was no comparison group consisting of patients
with diabetes without hypercholesterolemia, which may be
considered a limitation.
5. Conclusion
In summary, the presence or absence of diabetes should guide
the lipid parameters the clinician uses to predict cardiovascu-
lar risk and guide lipid-modifying therapies. Non-HDL-C may
be more sensitive than LDL-C in this regard. In Japanese
patients with type 2 diabetes and mild-to-moderate hyper-
cholesterolemia, non-HDL-C and the ratios of LDL-C/HDL-C
and TC/HDL-C ratios may be better predictors of cardiovascu-
lar risk than traditional lipid parameters. In Japanese mild-to-
moderate hypercholesterolemic patients without diabetes,
LDL-C/HDL-C and TC/HDL-C best predict cardiovascular risk.
Non-HDL-C is a particularly useful lipid parameter to assess
cardiovascular risk, because it is easy to calculate and is less
affected by food intake.
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